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Abstract
Background: Common deterrents to insulin therapy for both physicians and patients are the
complexity and burden of daily injections. In January 2006, the first inhaled human insulin (INH,
Exubera® (insulinhuman [rDNA origin])InhalationPowder) was approved for use in adult patients
with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) in the United States and
European Union. Results from the INH clinical trial program have shown comparable efficacy of
INH to subcutaneous (SC) insulin and superior efficacy versus oral antidiabetic agents; thus
providing effective glycemic control in adult patients with T2DM without the requirement for
preprandial injections. However, because subjects in those trials were randomized to either INH
or an alternative, the studies could not estimate the effect of INH on patient acceptance of insulin
therapy. Therefore, traditional study designs cannot provide answers to important and practical
questions regarding real world effectiveness, which is influenced by psychological and other access
barriers.
Methods: To overcome these limitations, the Real World Trial was designed to estimate the effect
of the availability of INH as a treatment option for glycemic control. A total of approximately 700
patients from Canada, France, Germany, Italy, Spain, United Kingdom, and the United States with
T2DM poorly controlled by oral agent therapy will be randomized to two different treatment
settings. Patients and clinicians in both groups (A & B) may choose from all licensed therapies for
diabetes including SC insulin delivered by pens; INH will be an additional treatment option only
available in Group A. The Real World Trial (Protocol A2171018) has been registered with
ClincalTrials.gov, registration id NCT00134147.
Results: The primary outcome for the trial will be the difference in mean glycosylated hemoglobin
(HbA1c) at 6 months between groups. The design was based on a preceding feasibility study
examining the theoretical effects of inhaled insulin availability on treatment choice in 779 patients.
In that study, patients were three times more likely to choose insulin therapy when inhaled insulin
was available.
Conclusion: Innovations in study designs may provide an opportunity to reveal unbiased answers
to important treatment questions that are more relevant to prescribers, funding agencies, and
healthcare policymakers.
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1.0 Background
Diabetes mellitus constitutes a major healthcare problem
globally. In the United States, 10.3 million people were
reported with this disease in 1997; and an additional 5.4
million people were suspected to have diabetes, but were
not diagnosed nor treated [1]. The total number of indi-
viduals with identified diabetes is expected to increase to
approximately 16 million by 2010 [2], and 22 million by
2025 [3]. Most patients have type 2 diabetes mellitus
(T2DM), characterized by a combination of insulin resist-
ance and progressive loss of insulin secretion. In approxi-
mately 58% of patients with T2DM, the disease is not
sufficiently controlled based on American Diabetes Asso-
ciation (ADA) recommendations [4]. As a result, patients
experience substantial morbidity and mortality due to
complications resulting from chronic exposure to hyperg-
lycemia [5-9] although major clinical trials have demon-
strated that improved glycemic control can significantly
reduce the risk of complications [10,11].
Oral antidiabetic agents (OAs) are the current mainstay of
T2DM management, but their long-term efficacy is lim-
ited by the progressive and irreversible loss of β-cell func-
tion, whereas insulin therapy remains continually
effective. However, initiation of insulin injections fre-
quently is restricted as a "last resort" for a variety of rea-
sons such as fear of needles, inconvenience, and
technique. Indeed, several studies have shown delays of 4
years or longer in the uptake of insulin therapy by patients
uncontrolled with multiple OAs [12,13]. This delay may
accelerate β-cell failure and disease progression and has-
ten development of complications, highlighting the need
for improved patient acceptance of insulin therapy so it
may be used in a timelier and appropriate manner.
Non-invasive methods of insulin delivery, such as inhaled
insulins, may increase the acceptance, and thus earlier ini-
tiation, of insulin therapy. The first inhaled human insu-
lin (INH, Exubera®  (insulinhuman [rDNA origin])
Inhalation Powder) was recently approved by the Euro-
pean Commission and the US Food and Drug Administra-
tion to deliver effective glycemic control in adult patients
with type 1 or type 2 diabetes. Phase 3 trials have demon-
strated that INH is as efficacious as subcutaneously (SC)
injected regular human insulin in type 1 diabetes (T1DM)
[14,15] or T2DM [16], and superior to OAs in T2DM [17-
20]. INH offers a number of potential advantages [14-29],
including a time-action profile that is more suited for
mealtime insulin administration compared with SC regu-
lar human insulin [21,22]. Another advantage of INH is
that patients with T2DM who are poorly controlled with
OAs are able to attain good glycemic control by simply
adding INH to their oral regimen [18,19]. In a 12-week
study by Rosenstock and colleagues, adjusted treatment
group differences from baseline (9.5–9.6%) in glyco-
sylated hemoglobin (HbA1c) of -1.2% and -1.7% were
observed when INH was substituted for combination OA
therapy or added to combination therapy, respectively
[18]. Furthermore, Phase 3 trial results indicate that INH
lowers HbA1c to ADA target levels (HbA1c < 7%) in more
than one third of patients after only 3 months of treat-
ment [16,18,20].
Evidence from completed Phase 2 and 3 studies up to 4
years in duration support that insulin administration via
the lung is generally well tolerated in patients with T1DM
or T2DM [12-20,23,24]. A slight, but clinically insignifi-
cant, decline in lung function was observed to a greater
extent in patients treated with INH compared with control
patients; this decline was nonprogressive and reversed
after discontinuation of INH therapy [14-16,19,23,24].
The only significant clinical adverse effect associated with
INH was cough, which was generally characterized as
mild to moderate in severity, decreased over time, and was
not associated with decline in lung function [14-16,19].
In extensions of several Phase 2 studies, patients appear to
be satisfied with INH, as evidenced by more than 85% of
subjects choosing to remain on INH [29]. Subjects also
demonstrated a preference for INH to SC insulin or OAs
when offered the choice [25-28].
This combination of attributes suggests that INH may be
a valuable addition to the treatment options available to
patients and physicians in attaining glycemic control.
However, these data on efficacy and safety cannot address
the overall health benefits and pharmacoeconomic
impact of INH in society. No randomized trials have
examined the potential advantages of increased uptake of
insulin due to avoidance of injections.
This paper describes the Real World Trial of INH, which
was designed to overcome the limitations associated with
traditional study design. The Real World Trial has adopted
a novel design in order to estimate the effects of the avail-
ability of INH on physician and patient acceptance of
insulin, health status (e.g. glycemic control), and health
economic parameters.
2.0 Methods
2.1 Study population
Approximately 700 patients with T2DM, aged 35 to 80
years with poor glycemic control despite treatment with
two or more OAs. Abstinence from smoking is required
because smoking greatly increases insulin absorption
[30,31].
2.2 Study design
The study is a 52-week, open label, randomized (1:1), par-
allel, multicenter study consisting of a 6-month core
phase to assess change in HbA1c, and a 6-month extensionTrials 2006, 7:25 http://www.trialsjournal.com/content/7/1/25
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phase to assess persistence of effects observed during the
initial trial phase. The study design is summarized in Fig-
ure 1. Patients will be randomized to one of two experi-
mental groups. In Group A, subjects will be given the
option to choose from all appropriate treatment options
including SC insulin delivered by either syringe or pen,
oral agents, and INH treatment. Study subjects rand-
omized to Group B will have the same treatment options
except INH will not be available. In both groups, irrespec-
tive of the availability of INH, patients may choose to
remain on their current treatment or start any other mar-
keted treatment. Patients and physicians are not under
any obligation to use INH in Group A. Choices made at
the beginning of the study can be revisited and changed
midway through the study.
2.3 Outcomes
This trial will provide an estimate of the effect of availabil-
ity of INH in general practice. The primary end point is
change from baseline HbA1c (%) after 6 months of treat-
ment between groups. Secondary efficacy end points
include:
￿ HbA1c at Week 52
￿ Proportion of patients achieving adequate glycemic con-
trol (HbA1c ≤ 6.5%, ≤ 7.0%)
￿ Time-to-insulin therapy initiation
￿ Change from baseline in fasting plasma glucose level
￿ Incidence and severity of hypoglycemia
￿ Change from baseline in body weight and body mass
index
￿ Change from baseline in fasting lipid profile
￿ Proportion of different treatment categories: INH, SC
insulin, changed OAs, no treatment change
￿ Treatment satisfaction
￿ Health status
Usual laboratory and clinical monitoring of adverse
events will assess safety.
Real World Trial Study Design Figure 1
Real World Trial Study Design.Trials 2006, 7:25 http://www.trialsjournal.com/content/7/1/25
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2.4 Sample size and analysis plan
A minimum sample size of approximately 279 patients
per group will be required to provide 90% power to detect
a difference between groups in the primary end point
HbA1c of at least 0.33% assuming that the standard devia-
tion does not exceed 1.2%. To protect against a possible
drop-out rate as high as 10%, approximately 650 patients
need to be enrolled.
The primary outcome will be analyzed by intention to
treat, using a mixed model. The primary analysis will
include treatment and number of OAs as fixed effects. It
also will include study centers as random effects due to
the large number of anticipated sites (approximately 90),
and baseline HbA1c (defined as the Week -1 HbA1c) will be
a patient-level covariate. A similar approach will be used
for other continuous outcome measures. Analogous non-
linear mixed models will be used to estimate the effect of
random allocation on dichotomous outcomes, incorpo-
rating study centers as random effects. An unstratified Cox
Proportional Hazards model will be used to estimate the
effect of random allocation on time-to-insulin initiation.
2.5 Study organization
The study has been accepted by regulatory authorities and
IRBs/IECs where the study is being conducted without
request for change. All laboratory data are handled by a
central contract laboratory. Quality assurance is being
provided by a global contract research organization. A
standing external advisory committee has provided input
into the design and conduct of the study since inception
of the aforementioned feasibility study.
3.0 Discussion
Estimating the potential benefits of INH on improved
insulin acceptance and glycemic control requires adapta-
tion of conventional randomized trial designs. The Real
World Trial will estimate the effects of insulin acceptance
on glycemic control while preserving the benefits of rand-
omization to reduce bias. Its design takes into account the
need for internal and external validity that the results are
attributable to the intervention (i.e. INH availability) and
that they may be applied to general practice. This design is
practical because patients and physicians have real life
choices that are normally "designed out" and removed in
a "classical" clinical trial. In this trial, physicians are able
to freely use the new treatment without some of the
restrictions of a traditional trial; physicians and patients
can interact normally in discussing, designing, and opti-
mizing treatment regimens. The study also will encom-
pass a variety of clinical practices including community
specialist and primary care to better reflect the expected
post-marketing use of the product. The findings from the
Real World Trial will provide important information that
can be generalized for clinicians and healthcare policy-
makers in distinguishing the role of INH by identifying
the association between INH availability/acceptability
and glycemic control, and establishing the effects on
resource use. Recruitment for the Real World Trial con-
cluded in spring 2006 after recruitment of 739 patients,
and results are expected in 2007.
A questionnaire-based feasibility study examining the the-
oretical effects of the availability of inhaled insulin on
treatment in 779 patients with T2DM who were not
achieving target glycemic control with their current ther-
apy was recently completed [32]. This randomized, con-
trolled trial provided supportive insight into the design of
the Real World Trial, as well as evidence that inhaled insu-
lin may lead to improved uptake of insulin. Treatment
preferences expressed by subjects of the feasibility study,
by number of OAs, are described in Table 1. In each
group, 77% of patients had HbA1c values greater than
10%, and the majority of patients were receiving treat-
ment with one or more OA along with dietary and lifestyle
advice. Patients were three times more likely to choose
insulin therapy when inhaled insulin was available (odds
ratio [OR]: 4.16; 95% confidence interval [CI]: 2.93 to
5.95, p < 0.0001) and significantly fewer patients in the
group offered inhaled insulin chose to make no change to
their therapy compared with patients offered standard
treatments only (OR: 0.49; 95% CI: 0.36 to 0.67, p <
0.0001). The proportion of patients choosing insulin in
both groups increased with the number of OAs currently
being taken, and inhaled insulin was the most frequently
chosen treatment option. Aversion to incorporating SC
insulin into therapy remained strong, despite high HbA1c
levels, and the availability of insulin pens in some coun-
tries. The enhanced willingness of those offered the
option of inhaled insulin treatment to change to a more
appropriate therapy increases the potential for achieving
improved glycemic control and reducing complications,
associated morbidity, premature mortality, and increased
cost of diabetes.
One of the key decisions that required consideration in
the design of the Real World Trial was the question of the
appropriateness of patient- or cluster-level randomiza-
tion. Rather than allocating patients between treatment
groups using a random process, cluster-level randomized
trials allocate patients in groups [33]. The rationale for
cluster-level randomized trials is apparent when treat-
ments cannot be applied to individuals, for example in a
trial of fluoridation of water supplies. Similarly, a cluster
trial would be appropriate when there is a risk of contam-
ination of treatments between groups, for example where
a healthcare professional was expected to provide differ-
ent levels of healthcare promotion advice to different
patients.Trials 2006, 7:25 http://www.trialsjournal.com/content/7/1/25
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Thus, cluster-level randomized trials are necessary in cer-
tain circumstances, but they are associated with a certain
disadvantage – we cannot consider patients allocated in
this way to be independent of each other. This lack of
independence must be addressed in the analysis. The
degree to which clustering affects the design of a study
depends upon the extent to which patients are clustered
within their units of allocation and the number of
patients per unit. However, patient per patient, a clustered
trial always will be less efficient than an individual patient
randomized trial. In addition, there are potential prob-
lems associated with the implementation of cluster-level
randomized trials. For example, when a trial intervention
is considered particularly attractive or of interest to inves-
tigating clinicians, the disappointment engendered from
being allocated to the control rather than experimental
condition may affect the behavior of the investigator.
Thus, control group investigators may recruit fewer
patients or different patients from those recruited by the
experimental group investigators, or they may experience
greater loss to follow up. The treatment of interest in the
Real World Trial may be applied to individual patients
without the risk of contamination; at the time of the study
enrollment INH was available only as an investigational
product. Thus, there is no requirement to move to a clus-
ter design and the associated issues regarding trial quality
and loss of efficiency.
4.0 Conclusion
The novel design of the Real World Trial, randomizing
patients to scenarios where different treatment options are
available for the management of their condition, is neces-
sary in order to provide an estimate of the potential utility
of the intervention in standard practice. Trials required for
the registration of a new product generally do not provide
such information, which is increasingly necessary for
healthcare policymakers and clinicians in an environment
where healthcare resources are limited. It is very likely that
we will see many more such trials in the future.
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